Study Shows Peritoneal Mesothelioma Surgery Underutilized

The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from, the highly effective procedure. Only a third of those diagnosed with peritoneal mesothelioma are undergoing potentially curative cytoreductive mesothelioma surgery, according to a comprehensive study of the National Cancer Database by researchers at Inova Fairfax Medical Center in Virginia. Annals of Surgical Oncology published the mesothelioma study earlier this year. “Patients who have the surgery perform much better than those who do not. Yet most people do not have surgery,” Dr. Timothy Cannon, medical oncologist at Inova Medical Group and study co-author, told The Mesothelioma Center at “We’re hoping the study can raise awareness to this paradox.” The research involved 2,062 adult patients registered with the National Cancer Database who were diagnosed with diffuse malignant peritoneal mesothelioma, a rare and aggressive cancer found within the abdominal cavity. Survival Advantage for Peritoneal Mesothelioma Is Dramatic An estimated 400 cases of peritoneal mesothelioma are diagnosed in the United States annually. It is typically caused by long-ago exposure to asbestos. Inova’s study found that nonsurgical patients had a median overall survival of just 7.1 months, compared to 38.4 months for surgical patients and 41.8 months for those who also added...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer. The long latency from asbestos exposure to MPM development, as well as the absence of early symptoms, lead to late diagnosis and very poor prognosis, with a life expectancy of 9-18 months from diagnosis [1]. Only a small number of patients is suitable for multimodal therapy, including surgery, and the majority of patients receive palliative chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis. The aim of this study was to identify genetic mutations associated with poor or extended survival in patients who received palliative chemotherapy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer, with a five-year survival rate of
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and mediastinal malignancies Source Type: research
The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,&rd...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study shows that the improvement in quality of life can be very significant compared with the preoperative status,” Levine said. “By six months, virtually all of the patients had recovered to preoperative baseline or better quality-of-life measures.” The post Quality of Life Still Good with HIPEC Surgery for Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A novel radiotherapy regimen can double the chances of surviving two or more years with pleural mesothelioma, according to Dr. Marco Trovo at University Hospital of Udine in Italy. Trovo is the lead author of a study involving 108 patients treated for malignant mesothelioma between 2014 and 2018 at the National Cancer Institute in Aviano, Italy. He presented the findings this week at the annual European Society for Therapeutic Radiology and Oncology convention in Milan. “Radiotherapy has evolved dramatically in the last few years, so we wanted to see if it could now be used to prevent cancer from spreading to nearby ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare thoracic solid tumor cancer that has been strongly linked to asbestos exposure. It has a long latency period of at least 20-30 years following exposure, and global incidence is still increasing in countries where asbestos is still in use. Surgical resection for patients with early stage MPM is considered standard therapy and radiation therapy offers only palliative benefit. For patients with advanced disease, combination chemotherapy with Cisplatin and Pemetrexed results in improvement in survival and quality of life, thus constituting the “standard of care”.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
ConclusionsSatisfaction with treatment was high, but participants identified need for improved communication and quality information, discussion about all treatments, end-of-life assistance, and caregiver support after the patient ’s death.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Databases & Libraries | Environmental Health | Mesothelioma | Palliative | Study | USA Health